These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8255496)

  • 41. Treatment of Guillain-Barré syndrome with intravenous immunoglobulin.
    Sater RA; Rostami A
    Neurology; 1998 Dec; 51(6 Suppl 5):S9-15. PubMed ID: 9851724
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Guillain-Barré syndrome.
    Ansar V; Valadi N
    Prim Care; 2015 Jun; 42(2):189-93. PubMed ID: 25979580
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 'Immunoglobulin therapy in Guillain-Barré syndrome in children'.
    Ganesan V; Kirkham FJ
    Dev Med Child Neurol; 1996 Apr; 38(4):371-2. PubMed ID: 8641543
    [No Abstract]   [Full Text] [Related]  

  • 44. Give or take? Intravenous immunoglobulin or plasma exchange for Guillain-Barré syndrome.
    Hughes RA
    Crit Care; 2011 Jul; 15(4):174. PubMed ID: 21888680
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasmapheresis vs intravenous immunoglobulin treatment in childhood Guillain-Barré syndrome.
    Vajsar J; Sloane A; Wood E; Murphy EG
    Arch Pediatr Adolesc Med; 1994 Nov; 148(11):1210-2. PubMed ID: 7921126
    [No Abstract]   [Full Text] [Related]  

  • 46. Management of Guillain-Barré syndrome (GBS).
    Hahn AF
    Baillieres Clin Neurol; 1996 Oct; 5(3):627-44. PubMed ID: 9117079
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function.
    Créange A; Bélec L; Clair B; Degos JD; Raphaël JC; Gherardi RK
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):162-5. PubMed ID: 9489524
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Campylobacter jejuni Infection and treatment for Guillain-Barré Syndrome.
    Jacobs BC; Schmitz PI; van der Meche FG
    N Engl J Med; 1996 Jul; 335(3):208-9. PubMed ID: 8657230
    [No Abstract]   [Full Text] [Related]  

  • 49. Guillian-Barre syndrome: issues in etiology and management.
    Garg RK
    Indian Pediatr; 1997 Jan; 34(1):74-7. PubMed ID: 9251289
    [No Abstract]   [Full Text] [Related]  

  • 50. Intravenous immune globulin in the Guillain-Barré syndrome.
    van der Meché FG
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):43-7. PubMed ID: 8033434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome.
    Farcas P; Avnun L; Frisher S; Herishanu YO; Wirguin I
    Lancet; 1997 Dec; 350(9093):1747. PubMed ID: 9413468
    [No Abstract]   [Full Text] [Related]  

  • 52. Guillain-Barré syndrome.
    Winer J
    Br J Hosp Med; 1994 Mar 16-Apr 5; 51(6):313. PubMed ID: 8032572
    [No Abstract]   [Full Text] [Related]  

  • 53. [Beneficial effects of plasma exchange in acute Guillain-Barré syndrome: comparison with methylprednisolone pulse therapy].
    Mori E; Yoshida T; Ohsumi Y; Tabuchi M; Yamadori A
    Rinsho Shinkeigaku; 1988 Feb; 28(2):196-203. PubMed ID: 3409619
    [No Abstract]   [Full Text] [Related]  

  • 54. Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome.
    Rajabally YA
    Neurotherapeutics; 2022 Apr; 19(3):885-896. PubMed ID: 35648286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group.
    Visser LH; van der Meché FG; Meulstee J; van Doorn PA
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):242-4. PubMed ID: 9489539
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Respective role of high doses of immunoglobulins and plasma exchange in the treatment of Guillain-Barré syndrome].
    Raphael JC
    Ann Fr Anesth Reanim; 1992; 11(4):473-4. PubMed ID: 1369621
    [No Abstract]   [Full Text] [Related]  

  • 57. Severe Guillain-Barré syndrome during childhood responding to intravenous gammaglobulin.
    Heaton PA
    N Z Med J; 1992 Nov; 105(946):477-8. PubMed ID: 1436876
    [No Abstract]   [Full Text] [Related]  

  • 58. Single-dose intravenous immune globulin for treatment of Guillain-Barré syndrome.
    McGhee B; Jarjour IT
    Am J Hosp Pharm; 1994 Jan; 51(1):97-9. PubMed ID: 8135270
    [No Abstract]   [Full Text] [Related]  

  • 59. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin.
    Voltz R; Rosen FV; Yousry T; Beck J; Hohlfeld R
    Neurology; 1996 Jan; 46(1):250-1. PubMed ID: 8559387
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term treatment of chronic relapsing inflammatory demyelinating polyradiculoneuropathy: combination of corticosteroids, plasma exchange, and intravenous immunoglobulins.
    Briellmann RS; Nydegger UE; Sturzenegger M; Fierz L; Hess CW; Hauser SP
    Eur Neurol; 1998; 39(3):190-1. PubMed ID: 9605400
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.